Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL27911471 | 0.94 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Demannose SCHEMBL7958057 | 0.93 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylose SCHEMBL5322348 | 0.93 | LMNA (0.43) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Demannose SCHEMBL537703 | 0.93 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Demannose SCHEMBL329074 | 0.93 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Demannose SCHEMBL28146511 | 0.93 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Demannose SCHEMBL3872401 | 0.93 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Galactose SCHEMBL6900501 | 0.93 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Demannose SCHEMBL2341216 | 0.91 | LMNA (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Demannose SCHEMBL9938071 | 0.91 | LMNA (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105622357-B | A kind of synthetic method of Dapagliflozin impurity | 合肥华方医药科技有限公司 | 2017-11-17 | — | — | CN | disclosed |
| CN-102046751-B | High porosity abrasive articles and methods of manufacturing same | SAINT GOBAIN ABRASIVES INC | 2013-08-28 | — | — | CN | disclosed |
| CN-102046751-A | High porosity abrasive articles and methods of manufacturing same | SAINT GOBAIN ABRASIVES INC | 2011-05-04 | — | — | CN | disclosed |
| EP-1986567-A2 | DRUG DELIVERY STENT WITH EXTENDED IN VIVO DRUG RELEASE | Conor Medsystems, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008024626-A2 | BIORESORBABLE STENT WITH EXTENDED IN VIVO RELEASE OF ANTI-RESTENOTIC AGENT | INNOVATIONAL HOLDINGS LLC (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1858442-A2 | EXPANDABLE MEDICAL DEVICE WITH OPENINGS FOR DELIVERY OF MULTIPLE BENEFICIAL AGENTS | Conor Medsystems, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007092833-A2 | DRUG DELIVERY STENT WITH EXTENDED IN VIVO DRUG RELEASE | CONOR MEDSYSTEMS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006098889-A2 | EXPANDABLE MEDICAL DEVICE WITH OPENINGS FOR DELIVERY OF MULTIPLE BENEFICIAL AGENTS | CONOR MEDSYSTEMS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099381-A1 | DRUG DELIVERY STENT WITH EXTENDED IN VIVO AND IN VITRO RELEASE OF ANTI-INFLAMMATORY | CONOR MEDSYSTEMS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-6620921-B1 | 1,2,3,5,6-penta-O-propanoyl-beta-D-glucofuranose in crystalline form; prepared by reacting D-glucose, boric acid and propanoic anhydride; useful for preparation of glycosides | INDUSTRIAL RESEARCH LIMITED (NZ) | 2003-09-16 | — | — | US | disclosed |
| WO-2001036435-A1 | GLUCOFURANOSES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2001-05-25 | — | — | WO | disclosed |